Mycofoli 720 Tablet contains Mycophenolate Sodium 720 mg, a high-potency immunosuppressant widely prescribed in organ transplant medicine to prevent graft rejection.
This tablet works by inhibiting inosine monophosphate dehydrogenase (IMPDH), suppressing T- and B-lymphocyte proliferation and reducing immune-mediated injury to transplanted organs. It is suitable for patients requiring higher-dose immunosuppression under close medical supervision.
Clinically, Mycofoli 720 Tablet is used in renal, hepatic, and cardiac transplant protocols, often as part of combination therapy with calcineurin inhibitors and corticosteroids, to maintain graft stability and long-term transplant success.
The tablet provides accurate dosing, consistent bioavailability, and reliable therapeutic outcomes, making it ideal for hospitals, transplant centers, specialty pharmacies, and clinics managing intensive post-transplant immunosuppressive therapy.
Common side effects may include nausea, diarrhea, abdominal discomfort, headache, and mild infections. Rare but serious effects include leukopenia, anemia, thrombocytopenia, severe infections, and allergic reactions.
Mycofoli 720 Tablet is indicated for the prevention of organ transplant rejection in renal, cardiac, or hepatic transplant recipients. It is also used for the management of select autoimmune disorders, under the guidance of a specialist.
Use Mycofoli 720 Tablet strictly under medical supervision. Regular monitoring of blood counts, liver and kidney function, and infection status is essential. Inform your doctor if you have active infections, bone marrow suppression, or are taking other immunosuppressive medicines. Avoid live vaccines during therapy. Seek immediate medical attention if fever, unusual bleeding, or severe infections occur.
Store in a cool, dry place below 25°C. Protect from light and moisture. Keep out of reach of children. Do not use beyond the expiry date.